1. Home
  2. JELD vs YARW Comparison

JELD vs YARW Comparison

Compare JELD & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JELD-WEN Holding Inc.

JELD

JELD-WEN Holding Inc.

SELL

Current Price

$0.84

Market Cap

152.7M

ML Signal

SELL

Logo Yarrow Bioscience Inc. Common Stock

YARW

Yarrow Bioscience Inc. Common Stock

N/A

Current Price

$16.05

Market Cap

154.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JELD
YARW
Founded
1960
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Forest Products
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.7M
154.5M
IPO Year
2016
2017

Fundamental Metrics

Financial Performance
Metric
JELD
YARW
Price
$0.84
$16.05
Analyst Decision
Hold
Strong Buy
Analyst Count
3
4
Target Price
$1.23
★ $57.33
AVG Volume (30 Days)
★ 1.2M
175.0K
Earning Date
11-03-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 33.33
EPS
★ N/A
N/A
Revenue
★ $3,211,181,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.14
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.93
$12.39
52 Week High
$3.27
$44.28

Technical Indicators

Market Signals
Indicator
JELD
YARW
Relative Strength Index (RSI) 28.94 39.97
Support Level N/A $12.39
Resistance Level $1.48 $20.57
Average True Range (ATR) 0.15 2.67
MACD -0.01 0.30
Stochastic Oscillator 1.56 38.90

Price Performance

Historical Comparison
JELD
YARW

About JELD JELD-WEN Holding Inc.

JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.

About YARW Yarrow Bioscience Inc. Common Stock

Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.

Share on Social Networks: